EDIFY

Welcome to the Brand page for “EDIFY”, which is offered here for Manufacturing of cell therapy platforms for others that trains t-cells to target multiple tumor associated antigens;pharmaceutical preparations for the treatment of cancer that educate immune cells, without viral, non-viral or other genetic modifications, to manufacture multi-tumor associated antigen t-cells;reagents for scientific and research use, for use in the manufacturing process of cell therapy platforms to train t-cells to target multiple tumor associated antigens; biochemical preparations in the form of biochemical platforms for scientific purposes, for the manufacturing of cell therapy that trains t-cells to target multiple tumor associated antigens;platform as a service (paas) featuring biological computer software platforms for developing drug products to improve ability to target tumor cells; platform as a service (paas) featuring biological computer software platforms for research and development of pharmaceuticals for use with cell therapy to manufacture tumor-targeted t-cell products and target tumor-specific antigens without genetic modification;.

Its status is currently believed to be active. Its class is unavailable. “EDIFY” is believed to be currently owned by “Mana Therapeutics, Inc.”